Core Viewpoint - The implementation of a unified medical service pricing mechanism in Gansu aims to address the long-standing issues of inconsistent pricing and project naming in healthcare services, enhancing the management of nearly 3,000 medical service price items across the province [1][2]. Group 1: Focus on Children - New nursing guidelines include pricing for "premature infant care" and "newborn care," which will be incorporated into the medical insurance payment system, reimbursed at the standard for Class A projects [2]. - Additional pricing items for children under six years old have been established to incentivize healthcare providers to offer higher quality services to young patients [2]. - The pricing mechanism acknowledges the value of nursing staff's expertise and labor in high-risk premature infant care, reflecting respect for medical professionals [2]. Group 2: Focus on the Elderly - The implementation of the pricing guidelines has significantly improved services for the elderly, introducing fees for home hospital beds, home care services, and palliative care [2]. - These new medical service price items allow elderly individuals with mobility issues to receive professional medical care at home, particularly during end-of-life stages, ensuring comprehensive physical and psychological support [2]. Group 3: Support for Innovation - Adjustments in medical service pricing have facilitated the clinical application of advanced technologies such as invasive brain-machine interface technology and AI-assisted diagnostics [2]. - The introduction of air medical transport projects will enhance the emergency rescue capabilities of hospitals, creating an efficient "air life channel" for the public [2]. Group 4: Overall Impact - The Gansu Provincial Medical Insurance Bureau aims to standardize hospital charges through these pricing adjustments, making healthcare access more convenient and strengthening medical security, ultimately improving the health satisfaction of the populace [3].

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical is a significant development, although her lack of experience in listed company secretary roles raises questions about her suitability for the position [3][6]. Company Overview - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields including gastrointestinal diseases, pediatrics, oncology, and more [6]. - The company has experienced significant performance fluctuations in recent years, primarily due to the impacts of the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [6]. Financial Performance - For the first half of 2025, Luoxin Pharmaceutical reported a revenue of 1.077 billion, a decrease of 14.45% year-on-year, while achieving a net profit attributable to shareholders of 17.695 million, marking a turnaround from losses in the previous year [6][7]. - The total revenue for the latest reporting period was 1.077 billion, with a total cost of 1.098 billion, resulting in an operating profit of 39.41 million, which is a 133.12% increase year-on-year [7]. - The net profit attributable to the parent company's shareholders was 17.695 million, reflecting a 119.95% increase compared to the same period last year [7]. Management Background - Jiang Ying, the newly appointed Secretary of the Board, has a strong academic background with dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [3][5]. - Prior to her appointment, Jiang Ying worked in various roles at Guotai Junan Securities, Everbright Pramerica Fund, and Guotai Fund, but lacks experience in listed company secretary positions [3][5].